Serial Number
98201920
Owner
ReNAgade Therapeutics Management Inc.Attorney
Jonathan M. GelchinskyFiling Date
Sep 28, 2023
CRST Trademark
Serial Number: 98201920
Trademark Classes
Class 1 - Chemicals
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Class 5 - Pharmaceuticals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Class 42 - Computer & Scientific
Scientific and technological services; industrial analysis and research services
Owner Contact Info
500 Forge Rd.
Watertown, MA 02472
Entity Type: 03
Legal Representation
Correspondence Address
Jonathan M. Gelchinsky Pierce Atwood LLP
254 Commercial Street
Portland, ME 04101
United States
Trademark Details
Filing Date
September 28, 2023
Registration Date
Not Registered
Published for Opposition
December 31, 2024
Goods & Services
Enzymes, nucleic acid molecules, and compounds and agents for modifying small RNAs with targeting agents for medical use, namely, use of the modified small RNAs in the gene editing industry; pharmaceutical preparations and therapeutic agents, namely, for gene therapy and mRNA regulation; pharmaceutical and biological preparations for medical use for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene therapy and mRNA regulation
Chemical and biological agents for scientific and research use, namely, for the modification of small RNAs with targeting agents and for regulating expression and levels of mRNA with the modified RNAs; enzymes for scientific and research purposes; enzyme preparations for use in modifying small RNAs and for use of modified small RNAs in the gene editing industry; Nucleic acid sequences for other than medical and veterinary purposes
Research and development in the field of technology and engineering RNAs with targeting agents for use in gene therapy and mRNA regulation; development of new technology for others for enabling the engineering and modification of RNA with targeting agents, namely, developing molecular and cellular biology reagents, techniques, and assays for use in the gene editing industry
